Royalty Pharma plc (RPRX) — SEC Financial Statements & Analysis

Royalty Pharma plc (RPRX) is a pharmaceutical preparations company, incorporated in X0. Royalty Pharma plc trades on Nasdaq as: RPRX. Royalty Pharma plc (RPRX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, Royalty Pharma plc carries a market cap of $24.85B, a P/E ratio of 16.15x, a P/B ratio of 2.54x, a P/S ratio of 9.80x, an enterprise value of $33.00B, and an EV/EBITDA multiple of 21.83x. On profitability, it posts a gross margin of 91.76%, an operating margin of 59.61%, a net margin of 60.68%, a Return on Equity (ROE) of 15.96%, a Return on Assets (ROA) of 8.07%, and a Return on Invested Capital (ROIC) of 8.66%. Per share, it reports EPS of $3.46, diluted EPS of $2.76, free cash flow per share of $6.69, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 10.01% year-over-year, net income growth of 9.67% year-over-year, and EPS growth of 4.36% year-over-year. On the balance sheet, it maintains a current ratio of 2.80x, a quick ratio of 2.80x, working capital of $1.13B, a debt-to-equity ratio of 1.03x, a debt ratio of 0.51, an interest coverage ratio of 4.19x, free cash flow of $2.98B (TTM), and net debt of $8.15B. Figures sourced from SEC EDGAR.

Market Cap

$24.85B

P/E TTM

16.15x

EPS TTM

$3.46

P/B TTM

2.54x

ROE TTM

15.96%

ROA TTM

8.07%

Debt To Equity

1.03x

Free Cash Flow TTM

$2.98B

Net Revenue TTM Growth 1Y

10.01%

Data as of 2026-06-30 · Source: SEC EDGAR